Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with Doxercalciferol or Placebo in Advanced Prostate Cancer
NCT00582582Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Docetaxel + Doxercalciferol with Docetaxel + Placebo (2 arms). Primary endpoint: Objective Response Rate at 12 weeks. Started Apr 2002; status: terminated.
02
Drugs
doxercalciferol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00582582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582582.